{
    "id": "dbpedia_8712_2",
    "rank": 22,
    "data": {
        "url": "https://podtail.com/en/podcast/progress-potential-and-possibilities/dr-reshmi-ghosh-ph-d-applied-scientist-microsoft-a/",
        "read_more_link": "",
        "language": "en",
        "title": "Dr. Reshmi Ghosh, Ph.D. - Applied Scientist - Microsoft AI Development Acceleration Program (MAIDAP) - Developing High-Impact Generative AI/Machine Learning Solutions – Progress, Potential, and Possib",
        "top_image": "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/1200x1200bb.jpg",
        "meta_img": "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/1200x1200bb.jpg",
        "images": [
            "https://podtail.com/media/img/logo.svg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/250x250bb.jpg",
            "https://tools.applemediaservices.com/api/badges/listen-on-apple-podcasts/standard-white/en-us?size=250x83&releaseDate=1653468840&h=4abd6d4e7d784893dd8fbc5c595f4a59",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/0e/d3/1f/0ed31f30-2d9d-4b24-3204-c6dfb2080a8c/mza_4782503810257277195.jpg/80x80bb.jpg",
            "https://podtail.com/media/img/icon_gold.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2023-08-22T10:00:00+00:00",
        "summary": "",
        "meta_description": "Send us a Text Message.Dr. Reshmi Ghosh, Ph.D. ( https://www.microsoft.com/en-us/research/people/reshmighosh/ ) is an Applied Scientist as part of Microsoft’s AI acceleration program, under their Offi... – Listen to Dr. Reshmi Ghosh, Ph.D. - Applied Scientist - Microsoft AI Development Acceleration Program (MAIDAP) - Developing High-Impact Generative AI/Machine Learning Solutions by Progress, Potential, and Possibilities instantly on your tablet, phone or browser - no downloads needed.",
        "meta_lang": "en",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "Podtail",
        "canonical_link": "https://podtail.com/en/podcast/progress-potential-and-possibilities/dr-reshmi-ghosh-ph-d-applied-scientist-microsoft-a/",
        "text": "Latest\n\nEarliest\n\nMost played\n\nMost popular\n\nSearch\n\nEpisodes\n\nSend us a Text Message.\n\nRonnie Vasishta is Senior Vice President, Telecom at NVIDIA ( https://blogs.nvidia.com/blog/author/ronniev/ ), where he leads all aspects of NVIDIA's telecom business from business management to product go-to-market strategy. His organization is responsible for defining and architecting next-generation virtualized, open 5G advanced and 6G networks, which act as a software-defined overlay on telecommunication networks powered by accelerated computing. His team is working with telecom operators around the world on their transformation journeys using NVIDIA’s full-stack accelerated computing platform and extensive developer ecosystems.\n\nRonnie joined NVIDIA in 2020 from Intel, where he most recently served as the vice president and general manager of the Network and Configurable Logic Division, Data Products Group. At Intel, Ronnie’s team managed the company’s programmable business with telecom manufacturers and communication service providers.\n\nRonnie formerly served as CEO of privately held eASIC, which focused on the telecom and storage markets and was sold to Intel in 2018. Previously, he was vice president of technical marketing at LSI Logic, a pioneer in the custom ASIC business. At LSI Logic he also held a series of engineering roles extending across wafer processing, chip design, IP and packaging.\n\nRonnie studied Electrical and Electronic Engineering at Nottingham Trent University.\n\nImportant Episode Resources -\n\nNVIDIA State of AI in Telecom 2024 Survey Report - https://www.nvidia.com/en-us/lp/industries/telecommunications/state-of-ai-in-telecom-survey-report/?ncid=ref-inor-605102-vt26\n\nNVIDIA AI Solutions for Telecommunications - https://www.nvidia.com/en-us/industries/telecommunications/?ncid=ref-inor-463257-vt26\n\n#RonnieVasishta #Telecom #NVIDIA #6G #Telecommunication #RadioAccessNetworks #DigitalTwins #ArtificialIntelligence #InternetOfThings #QuantumComputing #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nSend us a Text Message.\n\nProf. Dr. Alan Widgerow, MBBCh, FCS, MMed, FACS, is Division Chief, Research, Center for Tissue Engineering ( https://sites.uci.edu/ctelab/team/ ) and Adjunct Professor Plastic Surgery, Dept of Plastic Surgery, University of California, Irvine ( https://faculty.uci.edu/profile/?facultyId=6048 ) and Chief Scientific Officer and Head of Skin Science Center of Innovation at Galderma ( https://www.galderma.com/ ).\n\nProf. Widgerow is a plastic surgeon who ran a solo private practice in South Africa for over 20 years.\n\nProf. Widgerow completed his undergraduate and post-graduate studies at the University of the Witwatersrand, South Africa. He has held various positions in numerous academic and professional associations including that of President of the Association of Plastic and Reconstructive surgery of Southern Africa (APRSSA). He is author of over 190 plastic surgical related publications and 2 books. He was also the founder and medical director of 13 wound clinics in South Africa.\n\nProf. Widgerow relocated to Irvine California in Dec 2009 to pursue his interests in medical device innovations, cosmeceuticals and wound care, but he still plays an active role in academic medicine world-wide. In 2012 he was appointed to the Faculty of the University of California Irvine Plastic Surgery Dept as Full Adjunct Professor and Director of the Center for Tissue Engineering and in 2021 was appointed as its Division Chief of Research. He is involved in multiple projects related to adipose derived stem cell and adipose decellularized matrix, wound healing and transplantation. In 2018 he was awarded the Distinguished Faculty Mentor of the year Award by the Institute for Clinical and Translational Science, UCI.\n\nProf. Widgerow has developed and licensed multiple products in the US and South African markets. In 2015 he joined ALASTIN Skincare, Inc. an early start up professional skin care company as their Chief Medical Officer. Over the past 6 years he has spearheaded the scientific innovations team introducing multiple new products based on novel wound healing pathways. The resulting products have been validated with gene expression, in vitro and ex-vivo testing, biopsies, and multiple clinical trials resulting in a range of products that have surpassed previous scientific validations in this space. He continues to pursue patented novel concepts, peptide technologies and vigorous testing thus contributing to Alastin Skincare’s position as the fastest growing professional skin care company in the US for the past 4 years.\n\nIn 2021, Alastin Skincare was acquired by Galderma, the largest privately owned dermatology company in the world, and in June 2022, Prof. Widgerow was appointed Chief Scientific Officer of Galderma, Head of the Skin Science Center for Innovation and Head of Alastin innovations. He is involved in aesthetic, prescription and consumer product science research and development.\n\n#AlanWidgerow #CenterForTissueEngineering #PlasticSurgery #UniversityOfCalifornia #Irvine #ChiefScientificOfficer #SkinScience #Galderma #Dermatology #ExtracellularMatrix #StemCells #Exosomes #ECM #Aging #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nMissing episodes?\n\nClick here to refresh the feed.\n\nSend us a Text Message.\n\nDr. Ryan Potts, Ph.D. is Vice President and Head, Induced Proximity Platform at Amgen ( https://www.amgen.com/science/research-and-development-strategy/multispecifics-and-other-modalities ) which is focused on novel ways to bring two or more molecules in close proximity to each other to tackle drug targets that are currently considered “undruggable.” He also leads Amgen’s Research & Development Postdoctoral Fellows Program ( https://www.amgen.com/science/scientific-community-initiatives/postdoctoral-fellows ).\n\nDr. Potts obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center. During this time his lab focused on answering a long-standing question in cancer biology regarding the cellular function of cancer-testis antigen (CTAs) proteins. In 2011 he was appointed Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry at UT Southwestern Medical Center. His lab’s work defined a function for the enigmatic MAGE gene (Melanoma Antigen Gene) family in protein regulation through ubiquitination.\n\nIn 2016 Dr. Potts lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. There his lab continued to work on CTAs, with a focus on elucidating the biochemical, cellular, physiological and pathological functions of the MAGE gene family.\n\nIn 2020 Dr. Potts moved to Amgen, Inc. in Thousand Oaks, California to build a new department called the Induced Proximity Platform (IPP).\n\nImportant Episode Link - Amgen Molecular Matchmakers Science Cartoon -\n\nhttps://wwwext.amgen.com/stories/2020/10/new-video-multispecific-medicines-that-work-as-molecular-matchmakers?_gl=1*1ygduyj*_ga*Mjc5OTk2NDUzLjE3MjI0NTk5Nzc.*_ga_CBMSV0J9VL*MTcyMjQ2MzI0MS4yLjEuMTcyMjQ2MzUyMC4zOC4wLjA.\n\n#Amgen #RyanPotts #InducedProximityPlatform #MultispecificDrugs #UndruggableTargets #MolecularMatchmakers #PROTAC #RNATAC #Proteasome #Lysosome #UbiquitinLigases #Ubiquitination #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Ashwin Vasan, MD, PhD is the Commissioner of the New York City Department of Health and Mental Hygiene ( https://www.nyc.gov/site/doh/about/about-doh/the-commissioner.page ).\n\nDr. Vasan is a primary care physician, epidemiologist and public health expert with nearly 20 years of experience working to improve physical and mental health, social welfare and public policy for marginalized populations here in New York City, nationally and globally. Since 2014 he has served on the faculty at the Columbia University Mailman School of Public Health and Vagelos College of Physicians and Surgeons, and he continues to see patients as a primary care internist in the Division of General Medicine at New York-Presbyterian Hospital/Columbia University Irving Medical Center.\n\nDr. Vasan most recently served as the President and CEO of Fountain House, a national nonprofit fighting to improve health, increase opportunity, and end social and economic isolation for people most impacted by mental illness. During his tenure, he grew the organization from a New York-based community mental health organization to a national network across eight markets, and grew the budget by nearly $20 million annually. He helped navigate the organization through COVID-19 by driving new telehealth and digital mental health programs while its physical locations closed, as well as developing new community-based outreach and accompaniment programs. Further, Dr. Vasan led the creation of a national policy office in Washington, D.C., working to change national mental health policy on the issues of crisis response services and funding for and quality of community-based mental health services.\n\nFrom 2016 to 2019, Dr. Vasan served as the founding Executive Director of the Health Access Equity Unit at the NYC Department of Health and Mental Hygiene, which focused on the intersection of clinical and social services for the care of people involved in the justice system and other vulnerable populations — a first-of-its-kind government program in the nation. Under his leadership the team launched the NYC Health Justice Network — an innovative partnership between community-based primary care providers, criminal legal system reentry organizations, the Health Department and the Fund for Public Health — to embed tech-enabled, peer community health workers to promote health and wellness of people reentering the community from incarceration, and their families.\n\nEarly in his career, Dr. Vasan spent nearly a decade at the intersection of global health, HIV and primary care, working with the nonprofit Partners In Health (PIH) in Rwanda, Lesotho and Boston, and at the World Health Organization (WHO) in Uganda and Geneva. At PIH, he led efforts to improve integrated primary care and HIV care delivery using WHO Integrated Management guidelines and training. Dr. Vasan worked as a Technical Officer under Dr. Jim Yong Kim on the WHO/UNAIDS \"3by5 Initiative\" to expand HIV treatment access in the developing world, focusing on pricing and access to HIV medications, and on health worker training and education.\n\nDr. Vasan received his BA in Economics from the University of California, Los Angeles; his ScM in Epidemiology from the Harvard School of Public Health; his MD from the University of Michigan; and his PhD in Public Health from the London School of Hygiene and Tropical Medicine. He completed his clinical training in internal medicine-primary care at New York Presbyterian Hospital.\n\n#NewYorkCity #AshwinVasan #Commissioner #PublicHealth #GlobalHealth #HIV #SocialDeterminantsOfHealth #MentalHealth #PaulFarmer #ColumbiaUniversity #Aging #Healthspan #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast\n\nSupport the Show.\n\nSend us a Text Message.\n\nThe Davos Alzheimer's Collaborative ( DAC - https://www.davosalzheimerscollaborative.org/ ) is a pioneering worldwide initiative to cure Alzheimer’s disease and dementia, seeking to mirror the success of global efforts against infectious diseases such as HIV/AIDS, Covid, and Malaria. Absent effective action at scale around the world, by 2050, more than 150 million families and half a billion people will be personally impacted by Alzheimer’s, creating a social, financial, economic, and global security disaster of historic proportions. DAC was launched in Davos in 2021 by the World Economic Forum and the Global CEO Initiative on Alzheimer's Disease.\n\nDr. Tim MacLeod is the Director of the Systems Preparedness workstream of the Davos Alzheimer’s Collaborative (DAC) where he executes on a mission to facilitate the implementation of national, regional, and global commitments to provide access to future innovations in treatment, diagnosis, and care.\n\nDrawing on his background in implementation science and innovation consulting, Dr. MacLeod guides the development, execution, and dissemination of multi-site, real-world implementation studies that generate evidence about the facilitators and barriers to adopting and scaling novel technology in the ADRD space.\n\nBefore joining DAC, Dr. MacLeod led the award-winning human-centered design studio Bridgeable as Managing Director, where he worked with Fortune 500 companies in the financial service and health spaces on significant innovation initiatives.\n\nDr. MacLeod holds a Ph.D. in community psychology and has published widely on health innovation and implementation science. His research with the Mental Health Commission of Canada’s At Home/Chez Soi team scaled the Housing First model from 5 pilot sites to over 20 cities nationally through multi-level policy change.\n\nDr. Vaibhav Narayan is Executive Vice President at the Davos Alzheimer’s Collaborative (DAC), which he joined after 13+ years at Johnson & Johnson (J&J) where he was Vice President of Digital Health Innovation and Head of Data Science for Neuroscience R&D.\n\nAt J&J, Dr. Narayan created and led programs that utilized multi-modal data from ‘genomics to digital’ to understand disease subtypes and develop AI/ML driven digital health solutions for prevention, early detection, disease course monitoring and prediction in Alzheimer’s and neuropsychiatric diseases.\n\nDr. Narayan also previously served as Head, Discovery Informatics, Eli Lilly and Company, and as Director, Computational Sciences, Celera Genomics. He also currently serves a role as Chief Industry Officer, UK Mental Health Mission, University of Oxford.\n\nDr. Narayan obtained a PhD from Yale University in computational biology and an Executive MBA from Kellogg School of Management, Northwestern University.\n\nImportant Episode Links\n\nThe Davos Alzheimer’s Collaborative Healthcare System Preparedness\n\n(DAC-SP) Early Detection Blueprint - https://www.dacblueprint.org/\n\nAlzheimer's Association International Conference 2024 - https://aaic.alz.org/\n\n#Alzheimers #Dementia #Davos #Neurology #Neuroscience #HealthyAging #BrainHealth #TimMacLeod #VaibhavNarayan #DavosAlzheimersCollaborative #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Andrea Choe, MD, Ph.D. is the CEO and Co-Founder of Holoclara ( https://www.holoclara.com/ ), a company focused on creating novel, safe, orally bioavailable worm-derived therapeutics with a focus on indications such as allergies and autoimmune disorders.\n\nWhile pursuing her doctorate at the California Institute of Technology, Dr. Choe uncovered a unique pheromone language shared by roundworms that may have evolved over hundreds of millions of years.\n\nDr. Choe’s research, including her discovery of novel molecules derived from worms that blocked formation of disease in animal models of allergic and autoimmune disease, has led to advances in the fields of evolutionary biology and extreme biology. Her work has become the foundation of Holoclara’s technology and mission to pioneer a new class of therapeutics that can provide relief for millions of people living with chronic and debilitating diseases.\n\nDr. Choe is a winner of the Emerging Women Founders in Biotech Award. She received her MD at USC Keck School of Medicine and her PhD at Caltech.\n\n#CaenorhabditisElegans #WormDerivedTherapeutics #AutoimmuneDisease #Allergies #Nematodes #AndreaChoe #Holoclara #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Abdulelah Alhawsawi, MD is the CEO of Novo Genomics ( https://novogenomics.sa/ ), a company located in KSA with a vision of being the regionally trusted, globally recognized biotech leader in the field of genomics & multiomics.\n\nDr. Alhawsawi is the former Founding Director General of the Saudi Patient Safety Center ( SPSC - https://www.spsc.gov.sa/English/Pages/Home.aspx ), and MOH Advisor on Patient Safety and was involved in the core efforts establishing SPSC as a WHO Collaborating Center for patient safety policies and strategies (1 of only 5 WHOcc worldwide in this field).\n\nDr. Alhawsawi is a consultant to several national and international quality and safety organizations and recently became a board member and Vice President of the Global Sepsis Alliance ( GSA - https://globalsepsisalliance.org/ ) as well as a Board member of Joint Commission Resources Board. He was part of the Expert Panel on the 3rd Global Patient Safety Challenge of the WHO and chaired the Organizing Committee for the 4th Global Ministerial Summit on Patient Safety in Jeddah, Saudi Arabia.\n\nDr. Alhawsawi has helped introduce Patient Safety as a G20 priority in the 2020 G20 of Saudi Arabia. Currently, Dr. Alhawsawi is part of the WHO’s Global Patient Safety Action Plan Taskforce and is a Global Ambassador of the G20 Health & Development Partnership ( https://g20healthpartnership.com/dr-abdulelah-alhawsawi/ ).\n\nDr. Alhawsawi holds a bachelor’s degree in Medicine from King Abdulaziz University, Jeddah, Saudi Arabia, is Dual board certified in transplant and hepato-biliary surgery (American – Canadian), and he completed his training in Mount Sinai School of Medicine, New York. He is a member of numerous medical societies and national quality committees.\n\n#AbdulelahAlhawsawi #PatientSafety #SaudiArabia #PreventableHarm #Sepsis #AntimicrobialResistance #HealthDiplomacy #ScienceDiplomacy #NovoGenomics #Genomics #Multiomics #PersonalizeMedicine #Agrigenomics #Premarital #Prenatal #NewbornCare#HereditaryDiseases #Oncology#GeneticsCounseling\n\n#ClinicalGenetics\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Vanúsia Nogueira, Ph.D. is Executive Director of The International Coffee Organization ( ICO - https://icocoffee.org/ ), an organization focused on strengthening the global coffee sector and promoting it’s sustainable expansion in a market-based environment for the benefit of all actors in the Global Coffee Value Chain.\n\nDr. Nogueira comes from a family of coffee producers, and started her career at PwC Consulting, where she was a partner and worked for 15 years. She started working directly with coffee in 2002, always focusing on niche markets.\n\nDr. Nogueira served as executive director at the Brazilian Specialty Coffee Association (BSCA) from 2007 through April 2022 and took over as Executive Director at the International Coffee Organization in May 2022.\n\nDr. Nogueira holds a Ph.D. in Administration/Marketing from Rosario National University in Argentina, a BS in Systems Engineering and Administration from Pontifical Catholic University of Rio de Janeiro (PUC-RJ) and MBAs and post-MBA focusing on Management, Marketing and Advanced Project Management from Fundação Getulio Vargas-Rio de Janeiro (FGV-RJ).\n\nThe ICO was established in 1963 under the aegis of the United Nations and following the approval of the first International Coffee Agreement in 1962. And is the only intergovernmental organization for coffee, bringing together exporting and importing Governments. It currently represents 93% of world coffee production and 63% of world consumption.\n\nImportant Link - The Center for Circular Economy in Coffee - https://www.circulareconomyincoffee.org/\n\n#Coffee #InternationalCoffeeOrganization #CircularEconomy #ICO #Macroeconomics #CoffeeValueChain #VanusiaNogueira #MinasGerais #Brazil #Sustainability #Producers #Growers #UnitedNations #SpecialtyCoffee #Beverages #Tea #Cocoa #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Oren Milstein, Ph.D. is CEO and Board Member of StemRad ( https://stemrad.com/ ), a world leader in the provision of personal radiation protection solutions and is the first company to offer life-saving protection from penetrating ionizing radiation and is making the lives of first responders, military personnel, utility personnel, medical teams, and astronauts safer without compromising mission objectives. Comprised of radiation biology experts, nuclear physicists, designers, and engineers and backed by dozens of prominent doctors and scientists including three Nobel Laureates, StemRad provides cutting-edge technology to protect these heroes on Earth and beyond.\n\nDr. Milstein co-founded StemRad in 2011, shortly after the Fukushima Daiichi nuclear disaster in Japan. He has been leading R&D efforts ever since and was appointed CEO in February of 2016.\n\nDr. Milstein has more than 12 years of Life Sciences research experience; formerly, Dr. Milstein was an European Molecular Biology Organization (EMBO) fellow at NYU’s Skirball Institute of Biomolecular Medicine, where his research provided basic insights into the mechanism of T cell activation. Later in his career, as an NIH fellow at the Scripps Research Institute, he discovered a novel mechanism for iron deficiency anemia. Subsequently, Dr. Milstein focused his research on radiation-induced autoimmune hemolytic anemia.\n\nDr. Milstein received his Ph.D. degree from The Weizmann Institute of Science in 2008, where he developed novel strategies for successful bone marrow transplantation into irradiated subjects. He received his B.Sc., Magna Cum Laude, from The Hebrew University in Jerusalem. His research has resulted in several peer-reviewed publications and patents.\n\n#OrenMilstein #StemRad #PersonalRadiationProtection #GammaRadiation #Fukushima #Chernobyl #Israel #Nagasaki #Hiroshima #NuclearAccidents #USANCA #CBRN #WMD #DTRA #BoneMarrow #NuclearWar #Putin #Iran #KimJungUn #NASA #LockheedMartin #NationalGuard\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Jeffrey DellaVolpe, MD is Medical Director of the Adult Extracorporeal Membrane Oxygenation (ECMO) Program at Methodist Hospital, San Antonio, Texas. He is also the Medical Director of the Cardiovascular Intensive Care Unit at Methodist Healthcare System and the Texas IPS Critical Care Service Line ( https://texasips.com/jeffrey-dellavolpe-md/ ). He also serves as chair of the Joint Society of Critical Care Medicine/Extracorporeal Life Support Organization Task Force and has created a platform for ECMO training and ECMO transport ( https://ecmotransports.com/about/ ).\n\nECMO is a form of extracorporeal life support, providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of oxygen, gas exchange or blood supply (perfusion) to sustain life.\n\nDr. DellaVolpe served as a Flight Surgeon with the 27th Special Operations Wing where he deployed twice in support of Operation Enduring Freedom – Trans Sahara. After completing his fellowship, he was assigned to the San Antonio Military Medical Center where he served as a critical care physician and a member of the 59th Medical Wing Critical Care Air Transport Team and Acute Lung Rescue Team.\n\nDr. DellaVolpe is originally from Newport, RI. After receiving his bachelor’s degree at Dartmouth College, he went on to attend medical school at Tulane University School of Medicine. He then completed his residency in Internal Medicine at Tulane Medical Center and his fellowship in Critical Care Medicine at the University of Pittsburgh Medical Center.\n\nDr. DellaVolpe wrote The ECMO Book, published Elsevier Health Sciences, in 2023 ( https://www.us.elsevierhealth.com/the-ecmo-book-9780443111983.html ).\n\n#JeffreyDellaVolpe #MedicalDirector #ExtracorporealMembraneOxygenation #ECMO #MethodistHospital #SanAntonio #Texas #Cardiovascular #IntensiveCare #CriticalCare #LifeSupport #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. William Padula, PhD, MS, MSc, is Assistant Professor, Pharmaceutical & Health Economics and Fellow, Schaeffer Center for Health Policy & Economics, at the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences, University of Southern California ( https://healthpolicy.usc.edu/author/william-padula-phd/ ). His research explores the theoretical foundations of medical cost-effectiveness analysis, especially pertaining to issues around the value of vaccines, healthcare delivery and patient safety in hospitals for acquired conditions such as pressure injuries. He has received grant funding in the form of a Career Development Award from the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, and the PhRMA Foundation Frontier Award. He has authored 100+ scientific papers, letters and book chapters that have been published in leading medical, economic, and health policy journals. Dr. Padula is also Co-Founder & Principal of Stage Analytics ( https://stageanalytics.com/william-v-padula-phd/ ), a consulting firm that is committed to providing the highest quality of scientific solutions to advance health care. Dr. Padula is an Associate Editor of Value in Health, and serves on the editorial boards of Applied Health Economics and Health Policy and Journal of Clinical Nursing. His work has been featured in the New York Times, The Atlantic, The Hill, Forbes and other media. He is a past recipient of the Award for Excellence in Health Economics and Outcomes Research from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR); the Academy Health Outstanding Dissertation Award; and the Society for Advancement in Wound Care (SAWC) Young Investigator Award. He served as President for the U.S. National Pressure Injury Advisory Panel (NPIAP) from 2021-2022. He was also Commissioner for the American Nurses Credentialing Center (ANCC) Magnet® Recognition Program from 2016-2019. Dr. Padula has previously held appointments as an Assistant Professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore, USA, and as a postdoctoral fellow at The University of Chicago. He was a visiting scholar at the University of York Centre for Health Economics in York, UK, the Oxford Institute for Nursing, Midwifery and Allied Health in Oxford, UK, and the University of Technology Sydney in Sydney, Australia. He received his B.S. in Chemical Engineering from Northwestern University, M.S. in Evaluative Clinical Science from Dartmouth College, M.S. in Data Analytics from University of Chicago, and Ph.D. in Pharmaceutical Economics from University of Colorado.\n\n#HealthEconomics #USC #WoundCare #Pharmacy #PressureSores #Pharmaceuticals #WilliamPadula #HealthcareValue #Outcomes #WastefulSpending #Medicare #Medicaid #progresspotentialandpossibilities #IraPastor #podcast #podcaster #viralpodcast #STEM #Innovation #Technology #Science #Research\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Raj Yavatkar, Ph.D. is Chief Technology Officer at Juniper Networks ( https://www.juniper.net/us/en/the-feed/topics/raj-yavatkar.html ), where he has responsibility for charting the company’s technology strategy, leading and executing the company’s critical innovations and products for intelligent self-driving networks, security, Mobile Edge Cloud, network virtualization, packet-optical integration, and hybrid cloud. A technology and products pioneer throughout his career, Dr. Yavatkar has envisioned how emerging technologies can be applied to creatively solve enterprise and business problems ahead of competitors to help establish new product lines. Before joining Juniper, Dr. Yavatkar was at Google (GCP), where he led a large team of engineers to deliver cloud networking infrastructure and products for Google Cloud customers. Prior to that at VMware, he ideated a new product concept to address the private/hybrid cloud markets by defining VMware Cloud Foundation—an easy way to deploy and manage virtual clouds—leading a large product team to successfully deliver product to market. He started his career at Intel, rising to the position of Intel Fellow, a position he held for 10 years. During his various leadership roles there, Dr. Yavatkar was responsible for driving new product and R&D initiatives in many areas of software. He brings a wealth of experience in emerging technologies. He has been awarded more than 45 patents, published over 60 research papers, authored 5 Internet standards, and co-authored a book on internet quality of service. He is an IEEE Fellow and holds a PhD in Computer Science from Purdue University.\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Jasneet Bhullar, MD, MS, is a colorectal surgeon and member of the general surgery team, Ascension Providence Hospital, Michigan State University College of Human Medicine ( https://healthcare.ascension.org/find-care/provider/1316177876/jasneet-bhullar ), where he provides both surgical and non-surgical treatments for a range of conditions including pelvic floor disorders, fecal incontinence, colon and rectal cancer, hemorrhoids, and other complex issues of the colon and rectal system.\n\nDr. Bhullar is also a practitioner with the Cornerstone Medical Group ( https://www.cornerstonemedgroup.com/physicians-staff/jasneet-bhullar-md/ ), a multi-specialty group consisting of primary care and specialty physicians in the metro Detroit area, where he was responsible for earning recognition as an Medtronic InterStim™ Center of Excellence for his work with their MRI-compatible implantable neuromodulation technology for Fecal incontinence (FI).\n\nDr. Bhullar earned his medical degree at Guru Gobind Singh Medical College in India and completed residencies in general surgery through Government Medical College, India and Providence Hospital and Medical Centers — Michigan State University, and did a fellowship in colon and rectal surgery at the University of Minnesota. He is board-certified by the American Board of Surgery (ABS) and the American Board of Colon and Rectal Surgery (ABCRS).\n\nSupport the Show.\n\nSend us a Text Message.\n\nCary Claiborne is CEO of Adial Pharmaceuticals ( https://www.adial.com/ ), a clinical-stage biopharma company focused on developing therapies for the treatment of addiction and related diseases, specifically Alcohol Use Disorder (AUD). In the U.S. alone, an estimated 35 million people suffer from AUD, resulting in significant health, social and financial costs. Current treatment options present significant barriers to patient adoption, including abstinence and side effects, which can lead to social stigmatization.\n\nMr. Claiborne has over three decades of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies.\n\nMost recently, Mr. Claiborne served as Chief Financial Officer and director of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. He led Indivior’s spin-off from its then parent company, Reckitt Benckiser, to become an independent, publicly traded company.\n\nPrior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt.\n\nBefore joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc. during the company’s initial public offering.\n\nMr. Claiborne currently sits on the boards of NeuroSense Therapeutics, a clinical-stage drug development company that is advancing a treatment for people living with amyotrophic lateral sclerosis, and CytRx Corporation, a biopharmaceutical company focused on discovering and developing new cancer therapeutics.\n\nMr. Claiborne graduated from Rutgers University with a B.A. in Business Administration and earned his M.B.A from Villanova University and was a National Association of Corporate Directors (NACD) Governance Fellow.\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Valerie Sarisky-Reed, Ph.D. ( https://www.energy.gov/eere/person/valerie-sarisky-reed ) is the Director of the Bioenergy Technologies Office (BETO), in the Office of Energy Efficiency and Renewable Energy (EERE), at the U.S. Department of Energy's (DOE). In this role, she manages efforts to improve performance, lower costs, and accelerate market entry of bioenergy technologies. She assists in overseeing strategic planning to meet aggressive goals covered by the BETO research and development budget of approximately $250M annually, working with the U.S. Department of Energy's (DOE) national laboratories, academia, and industry.\n\nThe Bioenergy Technologies Office current focus areas include scaling up renewable hydrocarbon fuel technologies with an emphasis on sustainable aviation fuels as well as on the recycle and upcycle of plastics through DOE’s Plastics Innovation Challenge which aims to reduce ocean-bound plastic waste.\n\nDr. Sarisky-Reed has more than 30 years of experience in addressing energy and environmental issues faced by the United States and globally. In addition to her programmatic activities, she is a founding member of the Metabolic Engineering Working Group, chartered by the Biotechnology Research Subcommittee, an inter-agency coordinating committee under the Office of Science and Technology Policy.\n\nDr. Sarisky-Reed also spent two years serving the chief scientist at the U.S. Department of Agriculture, helping to build bridges between DOE and the U.S. Department of Agriculture in support of the bioeconomy. She also served as acting director for EERE's Wind Energy Technologies Office where she enabled the development of the most recent Multi-Year Program Plan with a heavy focus on bringing offshore wind to the United States.\n\nDr. Sarisky-Reed holds a Ph.D. in biochemistry from Georgetown University, and is a graduate of the U.S. Department of Commerce’s Senior Executive Service Career Development Program.\n\nImportant Link - Bioenergy Technologies Office 2023 Multi-Year Program Plan - https://www.energy.gov/sites/default/files/2023-03/beto-mypp-fy23.pdf\n\nSupport the Show.\n\nSend us a Text Message.\n\nProf. Noga Kronfeld-Schor, Ph.D. is Principal Investigator and Chair, Department of Zoology at Tel Aviv University ( https://en-lifesci.tau.ac.il/profile/nogaks ) where her research centers on environmental physiology with a focus on biological rhythms of diverse vertebrate species. Her research asks questions regarding the consequences and adaptive significance of these rhythms, as well as the interaction between physiological and endocronological processes and the evolutionary ecology of organisms and communities. She also is involved in studying the impact of events like global warming and light pollution on biodiversity, as well as on human and environmental health.\n\nProf. Kronfeld-Schor also serves as Chief Scientist of the Israeli Ministry of Environmental Protection ( https://www.gov.il/en/departments/units/chief_scientist_office ), where she provides strategic, scientific, and technological consultations that are aimed at promoting the environmental field in Israel in accordance with advancements being made in leading developed countries and OECD member countries.\n\nProf. Kronfeld-Schor has a BSc in Biology, an MSc in Zoology, magna cum laude and Ph.D. in Zoology, all from Tel Aviv University, and was a post-doctoral fellow at Boston University, in Zoology & Neuroendocrinology.\n\nIn addition to the roles mentioned above, Prof. Kronfeld-Schor has also served as a member of the board of directors of the Society for the Protection of Nature, was a member of the plenum and was head of the Scientific and Professional Committee of the Nature and Parks Authority, and has managed numerous national and international projects, and advised various government bodies and international organizations.\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. David Boucher, Ph.D. is Director, Infectious Disease Preparedness and Response, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services ( https://aspr.hhs.gov/Pages/Home.aspx ).\n\nThe HHS Administration for Strategic Preparedness and Response (ASPR) leads the nation's medical and public health preparedness for, response to, and recovery from disasters and other public health emergencies.\n\nASPR collaborates with hospitals, healthcare coalitions, biotech firms, community members, state, local, tribal, and territorial governments, and other partners across the country to improve readiness and response capabilities.\n\nDr. Boucher previously held several other critical roles in the organization, including as Chief of the Antivirals & Antitoxins branch at BARDA’s Anthrax, Botulinum, Ebola and Smallpox therapeutics program office, Acting Director for the Administration for Strategic Preparedness and Response's Office of Industrial Base Management and Supply Chain (IBM/SC) and serving as HHS’s lead negotiator for product development/procurement agreements for COVID-19 medical countermeasures.\n\nDr. Boucher has a Bachelor of Science (B.S.), Genetics, and a Doctor of Philosophy (PhD), Biochemistry and Molecular Biology from University of California, Davis.\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Eliah Overbey, Ph.D. is Assistant Professor of Bioastronautics at The University of Austin ( UATX - https://www.uaustin.org/people/eliah-overbey ) where she is involved in pioneering research in the field of astronaut health, specializing in spaceflight-induced genomic changes. Her work focuses on mapping changes in the human body during spaceflight and developing Earth-independent laboratories to make humans a multi-planetary species ( https://www.eliahoverbey.com/ ). Dr. Overbey comes to UATX from her previous position as a Research Associate at Weill Cornell Medicine. Dr. Overbey's most recent projects have analyzed genomic changes in astronauts from the SpaceX Inspiration4 mission, and she is currently working on data analysis and sample collection for the Axiom-2 and Polaris Dawn missions. Dr. Overbey’s work launched the Space Omics and Medical Atlas ( SOMA - https://soma.weill.cornell.edu/#main ), an online portal with the largest compendium of molecular measurements from astronauts. She also serves as Vice Chair of the Cornell Aerospace Medicine Biobank ( CAMbank - https://cambank.weill.cornell.edu/#main ), which is the first biorepository of samples from commercial astronauts. Dr. Overbey is also Chief Scientific Officer at BioAstra ( https://www.bioastra.org/ ), a non-profit developing healthcare systems for astronauts. Dr. Overbey received a B.S. in Computer Science from UC San Diego, a Ph.D. in Genome Sciences from the University of Washington, and was a Postdoctoral Associate in Computational Biomedicine in the laboratory of Dr. Christopher Mason.\n\nSupport the Show.\n\nSend us a Text Message.\n\nDr. Xiaorong He, Ph.D., MBA is Senior Vice President, Head of Global Development Sciences and U.S. Site Head of Non-Clinical Development at Boehringer Ingelheim Pharmaceuticals, Inc. ( https://www.boehringer-ingelheim.com/us ), where with over two decades of experience, her leadership focus lies in advancing transformative medicinal product development and fostering a culture of scientific excellence and engagement across her teams.\n\nPrior to this role, Dr. He was VP and Head of the Material & Analytical Sciences Department at Boehringer Ingelheim, leading a large team of multidisciplinary scientists to develop and apply scientific methods and tools to support new drug development of chemical and biological entities.\n\nDr. He has previously worked for several large pharmaceutical companies, including Pfizer, GSK, Pharmacia & Upjohn before joining Boehringer Ingelheim. She received her Pharmacy B.S. degree from Beijing Medical University, M.S. degree in Pharmaceutics from University of Minnesota, Ph.D. degree in Pharmaceutics from Purdue University and M.B.A. degree from Western Michigan University.\n\nDr. He has also taught several short courses, given numerous podium presentations at national and international conferences, published many peer-reviewed papers and book chapters, and held several patents. She has been a member of scientific and editorial advisory boards for the Journal of Pharmaceutical Sciences since 2013.\n\nDr. He has also been volunteering with organizations such as the United States Pharmacopeia (USP) since 2005, first with the Excipient Monograph Expert Committee (2005-2010), then with the General Chapter-Physical Analysis Expert Committee (2010-2015). She has served as the Chair of the General Chapters–Physical Analysis Expert Committee during the 2015–2020 cycle.\n\nBoehringer Ingelheim Open Innovation Portal - https://www.opnme.com/\n\nSupport the Show.\n\nSend us a Text Message.\n\nMaj. Gen. Dr. Paul Friedrichs, MD is the Inaugural Director of the Office of Pandemic Preparedness and Response Policy, at the White House ( OPPR - https://www.whitehouse.gov/oppr/ ), a permanent executive office aimed at leading, coordinating, and implementing actions to prepare for and respond to pathogens that could lead to a pandemic or significant public health-related disruptions in the U.S., and principal advisor on pandemic preparedness and response, appointed by President Biden. Dr. Friedrichs was previously the Joint Staff Surgeon at the Pentagon where he provided medical advice to the Chairman of the Joint Chiefs of Staff, the Joint Staff and the Combatant Commanders, coordinating all issues related to health services, including operational medicine, force health protection and readiness among the combatant commands, the Office of the Secretary of Defense and the services. He also led the development and publication of the initial Joint Medical Estimate and served as medical advisor to the Department of Defense COVID-19 Task Force. Dr. Friedrichs received his commission through the Reserve Officer Training Corps and his Doctor of Medicine (M.D.) from the Uniformed Services University. He has commanded at the squadron and group level, served as an Assistant Professor of Surgery and led joint and interagency teams which earned numerous awards, including “Best Air Force Hospital.” As Chair of the Military Health System’s Joint Task Force on High Reliability Organizations, he oversaw developing a roadmap to continuously improve military health care. As the Command Surgeon for Pacific Air Forces, U.S. Transportation Command and Air Combat Command, the general and his teams identified gaps, developed mitigation plans and enhanced readiness for future conflicts and contingencies.\n\nSupport the Show.\n\nShow more"
    }
}